{
  "generated": "2026-02-10",
  "source": "MCP Finance (get_customer_ltv) + Sales MCP pipeline data",
  "territories": [
    {
      "name": "Mid-Atlantic",
      "aka": "DC / Philadelphia / Baltimore",
      "states": ["PA", "MD", "DE", "VA", "DC"],
      "accounts": 8,
      "revenue2025M": 2.20,
      "gpDollarsM": 0.99,
      "avgGpPct": 45.2,
      "pipelineM": 4.2,
      "character": "Abbott-driven explosive growth, fastest in region",
      "topAccounts": ["Abbott Laboratories", "Spectranetics", "AstraZeneca UK", "Mallinckrodt"],
      "risks": ["88% revenue concentration in Abbott", "Spectranetics declining -51%", "LivaNova churned"],
      "opportunities": ["Abbott expansion to $2.5M+", "AstraZeneca expansion (93.8% GP)", "GSK Philly new logo"]
    },
    {
      "name": "NJ Pharma Corridor",
      "aka": "New Brunswick → Princeton",
      "states": ["NJ"],
      "accounts": 10,
      "revenue2025M": 2.02,
      "gpDollarsM": 0.82,
      "avgGpPct": 40.7,
      "pipelineM": 5.0,
      "character": "Big Pharma anchors, mixed margins, strong pipeline",
      "topAccounts": ["Bausch Health", "Regeneron", "Johnson & Johnson", "Integra LifeSciences"],
      "risks": ["J&J declining -18%", "Integra declining -49%", "Bausch 29.4% GP needs improvement"],
      "opportunities": ["Regeneron expansion (63% GP new logo)", "Merck & BMS new logos", "Novo Nordisk new logo"]
    },
    {
      "name": "Genetown",
      "aka": "Boston / Cambridge",
      "states": ["MA", "CT", "RI"],
      "accounts": 18,
      "revenue2025M": 1.35,
      "gpDollarsM": 0.58,
      "avgGpPct": 43.1,
      "pipelineM": 3.8,
      "character": "High-margin managed services, Takeda margin drag",
      "topAccounts": ["Takeda", "Harmony Biosciences", "Alnylam", "Ironwood", "Moderna"],
      "risks": ["Takeda at 14.5% GP drags blended margin", "Only 18 of 1000+ biotechs penetrated"],
      "opportunities": ["Takeda margin recovery ($179K profit swing)", "Moderna expansion", "Vertex/Sarepta/Biogen new logos"]
    },
    {
      "name": "Research Triangle",
      "aka": "Raleigh-Durham, NC",
      "states": ["NC"],
      "accounts": 0,
      "revenue2025M": 0,
      "gpDollarsM": 0,
      "avgGpPct": 0,
      "pipelineM": 1.1,
      "character": "GREENFIELD — Zero revenue, massive CDMO/CRO opportunity",
      "topAccounts": [],
      "risks": ["Zero penetration in major life sciences hub", "No dedicated seller"],
      "opportunities": ["IQVIA, Fujifilm Diosynth, PPD targets", "CDMO expansion wave", "$1M+ Year 1 target"]
    }
  ],
  "currentSellerAssignments": {
    "Mike Campbell": {
      "pipeline": 5.42,
      "opps": 87,
      "winRate": 14.9,
      "status": "NEEDS_COACHING",
      "currentTerritory": "NJ Pharma / Mid-Atlantic"
    },
    "Justin Ott": {
      "pipeline": 4.42,
      "opps": 61,
      "winRate": 74.8,
      "status": "STAR_PERFORMER",
      "currentTerritory": "NJ Pharma / Genetown"
    }
  },
  "recommendedAlignment": {
    "Mid-Atlantic": {
      "primarySeller": "Dedicated AM (Abbott focus)",
      "rationale": "Abbott at $1.94M needs dedicated attention + expansion across divisions",
      "expectedOutcome": "Grow Abbott to $2.5M+, add 3 new logos"
    },
    "NJ Pharma": {
      "primarySeller": "Justin Ott (star performer)",
      "rationale": "Highest win rate (74.8%) on highest-value targets (Regeneron, J&J, Bausch)",
      "expectedOutcome": "Expand Regeneron, save J&J/Integra, new Merck/BMS logos"
    },
    "Genetown": {
      "primarySeller": "Scott Pallardy + Vega Finucan",
      "rationale": "Dense territory with 18 accounts needing managed services focus",
      "expectedOutcome": "Takeda margin recovery, Moderna expansion, 5+ new logos"
    },
    "Research Triangle": {
      "primarySeller": "Partner Channel + Part-time AM",
      "rationale": "Greenfield territory needs investment before dedicated seller",
      "expectedOutcome": "$1M+ Year 1 revenue from CDMO/CRO targets"
    }
  },
  "terminology": {
    "territory": "Geographic zone grouping accounts by regional life sciences ecosystem",
    "pipeline": "Open opportunity amount (not yet won)",
    "bookings": "Won opportunity amount (contract value at close)",
    "revenue": "GAAP recognized (when billed/delivered)",
    "egp": "Estimated Gross Profit (projected margin at booking)",
    "gp": "Actual Gross Profit (realized margin after delivery)"
  }
}
